The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Testosterone and male hormones
What does it do to testosterone?
Measured hormone levels, and separately whether anything changed as a result.
12,336 people · 15 human studies · 11 compounds
- 5,246 people2 studies1 found nothing
TRAVERSE. 5,246 men aged 45 to 80 with preexisting or high risk of cardiovascular disease, symptoms of hypogonadism and two fasting testosterone levels below 300 ng/dL, randomised double-blind to transdermal testosterone gel titrated to 350 to 750 ng/dL or placebo. Mean treatment 21.7 months, mean follow-up 33.0...
New England Journal of Medicine, 2023 · 5,246 people
found nothingThe T-Trials. Treatment raised testosterone into the mid-normal range for men aged 19 to 40. Sexual activity, sexual desire and erectile function all improved significantly. Vitality did not improve on the fatigue scale. The proportion improving 6-minute walking distance by at least 50 m did not differ in the Physical...
New England Journal of Medicine, 2016 · no headcount in the line
- 5,246 people1 study
TRAVERSE, 5,246 men, no excess of cardiovascular death, heart attack or stroke against placebo. Included because it is the safety context for any testosterone ester, with the qualifier that TRAVERSE used a transdermal gel titrated to a defined range rather than an injectable.
New England Journal of Medicine, 2023 · 5,246 people
- 964 people3 studies
Pooled analysis of 920 men from nine prospective studies, with testosterone as the primary endpoint. The proportion reaching testosterone below 20 ng/dL was 79 percent at month 1, then 92, 93, 90 and 91 percent at months 3, 6, 9 and 12. This is a pooled analysis of prospective studies, not itself a randomised trial,...
Advances in Therapy, 2017 · 920 people
International phase 3 study at 18 centres in the United States, Chile and Mexico, in 44 treatment-naive children, 39 girls and five boys. 41 of 44 (93.2 percent) had prepubertal stimulated luteinising hormone at or below 5 IU/L at month 6, rising to 97.7 percent at month 12. Note the design: non-comparative and...
Journal of Pediatric Endocrinology and Metabolism, 2016 · 44 people
A randomised phase 3 trial in which triptorelin is the background androgen deprivation given to both arms while the randomisation tests immediate versus early salvage radiotherapy. Included here as the correction it represents: trials like this are frequently listed as triptorelin evidence, and they tell you about...
The Lancet Oncology, 2020 · no headcount in the line
- 610 people1 study
610 men with prostate adenocarcinoma, median age 72, randomised to two degarelix regimens or monthly intramuscular leuprolide. Testosterone at or below 0.5 ng/mL at every monthly measurement from day 28 to day 364 in 97.2, 98.3 and 96.4 percent respectively, meeting non-inferiority. At day 3, testosterone was at or...
BJU International, 2008 · 610 people
- 199 people1 study
199 patients: leuprolide suppressed testosterone comparably to DES with far fewer gynecomastia, nausea, edema and thromboembolic events.
New England Journal of Medicine, 1984 · 199 people
- 30 people1 study
30 men with BMI at or above 26, randomised double-blind to 250 mg of a 10 percent forskolin extract twice daily or placebo for 12 weeks. Body fat percentage and fat mass on DXA fell significantly against placebo, bone mass changed significantly, serum free testosterone rose significantly, and lean body mass showed a...
Obesity Research, 2005 · 30 people
- 29 people1 study
Randomized study in 29 men: low-dose hCG every other day preserved intratesticular testosterone during exogenous testosterone.
Journal of Clinical Endocrinology and Metabolism, 2005 · 29 people
- 6 people2 studies
Kisspeptin-54, not kisspeptin-10. First human kisspeptin study: a 90-minute infusion significantly raised LH, FSH and testosterone in six men.
Journal of Clinical Endocrinology and Metabolism, 2005 · 6 people
IV bolus kisspeptin-10 tripled LH in healthy men within 30 minutes; a 22.5-hour infusion raised LH and testosterone and increased LH pulse frequency.
Journal of Clinical Endocrinology and Metabolism, 2011 · no headcount in the line
- 6 people1 study
Pulsatile subcutaneous GnRH by pump normalized gonadotropins within a week, raised testosterone from 77 to 520 ng/dL in one month and produced spermatogenesis in three of six hypogonadotropic men.
New England Journal of Medicine, 1982 · 6 people
- no headcount stated1 study
Cetrorelix prevented premature LH surges (1.6% LH rise) with fewer gonadotropin ampoules and stimulation days than buserelin.
Human Reproduction, 2000 · no headcount in the line
- no headcount stated1 study
Raised testosterone while preserving sperm concentration.
Fertility and Sterility, 2014 · no headcount in the line
- no headcount stated0 studies
Independent replication of the mechanism: FOXO4-DRI induced p53 nuclear exclusion and apoptosis in senescent Leydig cells and improved testosterone secretion in naturally aged mice.
Aging, 2020 · no headcount in the line
- no headcount stated0 studies
Interventions Testing Program. 17-alpha-estradiol at a threefold higher dose than previously tested robustly extended both median and maximal lifespan, still only in males. The same paper reports nordihydroguaiaretic acid replicated in males at the original dose and at threefold lower and higher doses,...
Aging Cell, 2016 · no headcount in the line
- no headcount stated0 studies
The original report of the male-preferential lifespan effect, alongside acarbose and 17-alpha-estradiol.
Aging Cell, 2014 · no headcount in the line
- no headcount stated0 studies
found nothingThe relevant lifespan null for the nicotinamide riboside half of this product. In the National Institute on Aging Interventions Testing Program, genetically heterogeneous UM-HET3 mice fed nicotinamide riboside from 8 months of age showed no significant effect on lifespan in either sex in the pooled three-site dataset,...
Aging Cell, 2021 · no headcount in the line
- no headcount stated0 studies
A new osteocalcin-deficient mouse made by deleting Bglap and Bglap2. Bone quantity, glucose metabolism, testosterone synthesis and muscle mass were all normal. What was abnormal was the crystallographic orientation of bone apatite, and bone strength fell as a result. The authors conclude osteocalcin does not function...
PLoS Genetics, 2020 · no headcount in the line
- no headcount stated0 studies
C2C12 myotubes treated with 15 micromolar urolithin B for 24 hours grew and differentiated more, through increased protein synthesis and repression of the ubiquitin-proteasome pathway, with the androgen receptor implicated. In mice, 10 micrograms a day delivered continuously by implanted mini-osmotic pump for 28 days...
Journal of Cachexia, Sarcopenia and Muscle, 2017 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.